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Abstract Periostin, also called osteoblast-specific factor 2,
is a secreted cell adhesion protein, which shares a
homology with the insect cell adhesion molecule fasciclin
I. It has been shown to be an important regulator of bone
and tooth formation and maintenance, and of cardiac
development and healing. Recent studies revealed that
periostin plays an important role in tumor development
and is upregulated in a wide variety of cancers such as
colon, pancreatic, ovarian, breast, head and neck, thyroid,
and gastric cancer as well as in neuroblastoma. Periostin
binding to the integrins activates the Akt/PKB- and FAK-
mediated signaling pathways which lead to increased cell
survival, angiogenesis, invasion, metastasis, and impor-
tantly, epithelial-mesenchymal transition of carcinoma cells.
In this review we summarize recent clinicopathological
studies that have investigated periostin expression in lung,
kidney, prostate, liver cancer, and malignant pleural
mesothelioma and discuss the role of periostin isoforms in
tumorigenesis and their potential as targets for stroma-
targeted anticancer therapy.
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Background
Periostin, also termed osteoblast-specific factor 2, is a 93.3-kDa
secreted protein and shares a homology with the insect
cell adhesion molecule fasciclin I. It promotes integrin-
dependent cell adhesion and motility and belongs to the
superfamily of TGF-β-inducible proteins [1, 2]. Its N-
terminal region contains a signal peptide (SP) for its
secretion, and a cysteine-rich region (EMI domain) which
promotes the formation of multimers in non-reducing
conditions. Adjacent to the SP and the EMI domains, four
internal homologous repeats (FAS domains) are located;
these are homologous to the insect cell adhesion protein
fasciclin I and act as ligands for the integrins [1, 2]. The
C-terminal region of periostin consists of a hydrophilic
domain. The N-terminal region of periostin is highly
conserved, while the C-terminal region of the protein
varies depending on the isoform [1, 3]. The N-terminal
region regulates the cell function by binding to integrins at
the plasma membrane of the cells through its FAS
domains. The C-terminal region of the protein regulates the
cell–matrix organization and interactions by binding extracel-
lular matrix (ECM) proteins such as collagen I/V, fibronectin,
tenascin C, acid mucopolysaccharides, such as heparin and
periostin itself [4]. Periostin was shown to be able to bind the
integrins αvβ3, αvβ5, and α6β4, promoting the recruitment
of the epidermal growth factor receptor (EGFR) and the
activation of the Akt/PKB and FAK-mediated signaling
pathways. Periostin-activated signaling pathways promote
cellular survival, angiogenesis, and resistance to hypoxia-
induced cell death. Additionally, periostin can be upregulated
in response to the stress of hypoxia in the human A549 non-
small cell lung cancer cell line and in rat pulmonary arterial
smooth muscle cells (PASMCs) [5, 6]. The study of Li et al.
demonstrated that upregulation of periostin in PASMCs is
mediated through Ras signaling [6] (Fig. 1).
The desmoplastic tumor stroma constitutes the so-called
tumor microenvironment, which supports growth, invasion,
and immune evasion of the tumor. It is formed by a stromal
matrix in which cancer cells and the peri-tumoral stromal
L. Morra :H. Moch (*)




Virchows Arch (2011) 459:465–475
DOI 10.1007/s00428-011-1151-5
cells are embedded. The tumor stromal cells consist of
tumor-associated endothelial cells (TECs), cancer-
associated fibroblasts (CAFs), and tumor-associated macro-
phages, as well as distinct sets of tumor-directed lympho-
cytes. All these cell types produce growth factors,
angiogenic factors, and proteolytic enzymes which sustain
the tumor growth and angiogenesis and degrade the ECM,
enhancing the tumor cell invasion and metastasis [7].
Furthermore, an excessive production of ECM proteins
such as periostin, collagen, and fibronectin may contribute
to the generation of a tumor-supportive microenvironment
(Fig. 2). Within this context, the matrix protein periostin
(gene POSTN) plays an important role, regulating cell
function and cell–matrix interactions.
Periostin probably exerts its pro-tumorigenic effect
not only through its binding to the integrins and the
consequent activation of intracellular pathways which
determine an enhanced invasiveness, but also through its
effect on the ECM fibrillogenesis. The C-terminal
region of periostin has been shown to interact with
ECM molecules by immunoprecipitation and binding
assays [4, 8]. Together with those studies showing
colocalization of periostin with fibronectin, collagen, and
tenascin C [8], these findings suggest that periostin
regulates collagen fibrillogenesis and biomechanical prop-
erties of connective tissues, forming reticular structures.
Considering that alterations in the ECM components of
the tumor microenvironment have a remarkable impact on
the invasive and metastatic process, it is possible that
periostin promotes an ECM organization that supports
invasion and metastasis (Fig. 3).
Periostin protein is physiologically expressed in a wide
variety of normal adult tissues and fetal tissues, such as
embryonic periosteum, periodontal ligament, placenta,
cardiac valves, adrenal glands, lung, thyroid, stomach,
colon, vagina, ovary, testis, prostate, and breast [1, 9].
Moreover, periostin is expressed in tissues under stress
conditions, such as heart under pressure or volume
overload, skeletal muscle after injury, and in pulmonary
aortic smooth muscle cells in response to hypoxia [6, 10,
11]. Periostin has been shown to be essential for bone and
tooth formation and maintenance [2], for heart develop-
Fig. 1 Periostin-activated sig-
naling pathways. Periostin bind-
ing to integrins initiates the
crosstalk between those integ-
rins and the receptor tyrosine
kinases (RTKs), such as EGFR,
at the plasma membrane. This
crosstalk activates the Akt/PKB
and the FAK-mediated signaling
pathways. Ras signaling acti-
vates periostin under hypoxic
conditions. Reprinted from [69]
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ment, and healing after acute myocardial infarction [12].
Periostin-deficient mice have a mild phenotype character-
ized by alterations in periodontal ligament and craniofacial
ECM [13], structural valvular anomalies [14], and reduced
fibrosis after myocardial infarction [15].
Periostin upregulation has been reported for many
cancer types, as non-small cell lung cancer (NSCLC),
renal cell carcinoma (RCC), malignant pleural mesothe-
lioma (MPM), and others [16–21] and is consequently
defined as a tumor-enhancing factor. Only a few reports in
bladder cancer and osteosarcoma have described periostin
as a tumor-inhibiting factor [22, 23]. Moreover periostin
upregulation has been reported also for chronic sinusitis
and recent studies suggest that periostin may be part of a
negative-feedback loop regulating allergic airway inflam-
mation [24, 25]. Importantly, periostin is involved in the
epithelial-mesenchymal transition (EMT) of carcinoma
cells [6, 17, 19, 26, 27].
In this review, we summarize the current knowledge
about the role of periostin in the process of EMT and
discuss its potential as a target for anticancer therapies
directed against the tumor stroma. Furthermore, we sum-
marize current knowledge about periostin expression in the
different tumor components of NSCLC, MPM, prostate
cancer (PC), RCC, hepatocellular carcinoma (HCC), and
bile duct carcinoma (BDC) [16, 20, 21, 28, 29] (Table 1).
Epithelial-mesenchymal transition and periostin
It is well known that the EMT process is fundamental
during the embryonic development of multicellular organ-
isms [30]. In addition to embryonic development, the EMT
also participates in tumor progression. This is not unex-
pected, considering that analogies between the two pro-
cesses (embryonic development and tumor progression)
frequently occur. An increasing number of genes and
signaling pathways that are involved in embryonic devel-
opment are also found to be involved in tumorigenesis [31].
However there is much evidence that the EMT process is
responsible for dissemination of primary tumor epithelial
cells to the sites of metastasis and for the dedifferentiation
program that leads to increased malignant behavior of the
tumor [30] (Fig. 4).
On a morphologic basis, EMT in vitro can be
recognized by the presence of spindle-shaped cells,
emission of pseudopodia, and increased intercellular
separation, which reflects the acquisition of a mesen-
chymal phenotype, increased motility, and loss of cell–
cell adhesion. Furthermore, the EMT of cancer cells is
characterized by an upregulation of mesenchymal pro-
teins such as periostin, vimentin, fibronectin, and N-
cadherin, accompanied by a downregulation of epithelial
markers such as E-cadherin.
Fig. 2 Tumor microenviron-
ment and its influence on tumor
development. Tumor stromal
cells, e.g., CAFs, TECs, and
tumor-associated macrophages
(TAMs), express growth
factors sustaining tumor growth.
Among these are angiogenic
factors promoting angiogenesis,
proteolytic enzymes catalyzing
the degradation of the ECM,
and ECM proteins creating a
tumor supporting environment.
All these factors together
regulate tumor cell growth,
invasion, and finally metastasis.
Tumor cells are depicted in
brown, CAFs in orange, TECs
in red, and TAMs in yellow.
Reprinted from [7]
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On a functional basis, gain of N-cadherin expression,
together with loss of E-cadherin, leads to alterations in the
epithelial cell shape and motility by dissociation of
intercellular adherens junctions, promoting only weak
homophilic cell adhesion interactions [30, 31]. In vitro,
lack of E-cadherin determines acquisition of a mesenchy-
mal phenotype and invasive behavior, which can be
reversed if E-cadherin is restored and constitutively
expressed [32]. In vivo, it has been shown that E-
cadherin-negative cell lines have an increased tumorigenic
potential when implanted as xenografts in nude mice [30].
Clinical studies showed that E-cadherin expression is
inversely correlated with high-grade cancers or with poor
survival [33, 34]. On a molecular basis, E-cadherin is
Fig. 3 The role of periostin in cancer. The N-terminal region of the
protein influences cell function, while the C-terminal influences cell–
matrix interactions. Through its FAS domains, periostin binds to
integrins and activates the Akt/PKB and the FAK-mediated signaling
pathways, leading to increased tumor invasion and metastasis. The C-
terminal region of periostin binds extracellular matrix (ECM)
molecules and influences the general organization of the extracellular
matrix. Periostin splice isoforms differ in the C-terminal and it is still
not known if they contribute differentially to ECM formation and to
the global invasive and metastatic potential of the protein
Table 1 Overview of correlations found, by immunohistochemical studies on NSCLC, MPM, PC, RCC, and BDC tissue microarrays (TMAs),
between epithelial and stromal periostin expression and clinicopathological parameters
Tumor type Poor survival Differentiation grade Stage of disease Reference
Non-small cell lung cancer Stromal expression Epithelial and stromal
expression
Soltermann et al. [16]
Malignant pleural
mesothelioma
Epithelial expression Schramm et al. [20]
Prostate cancer Stromal expression Epithelial and stromal
expression
Epithelial expression Tischler et al. [28]
Renal cell carcinoma Epithelial expression Epithelial and stromal
expression
Epithelial expression Dahinden et al. [21]
Bile duct carcinoma Epithelial expression Riener et al. [29]
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downregulated by epigenetic mechanisms, such as pro-
moter hypermethylation and transcriptional repression.
Transcriptional repressors of E-cadherin are the zinc
finger proteins Snail and SIP1 and the basic helix-loop-helix
transcription factor Twist, all of which have the ability to
recognize and bind E boxes in the E-cadherin promoter
[35–37]. Snail, SIP1, and Twist are therefore inducers of
EMT and promote tumor cell invasion. Activation of
several growth factor receptors, including tyrosine kinase
receptors such as the hepatocyte growth factor receptor c-
Met, the ErbB protein family, and the fibroblast growth
factor, the insulin growth factor, and the transforming
growth factor-β (TGF-β) receptors, have been found to
induce EMT in vitro and in vivo [38–41]. Downstream
effectors of these activated receptors belong to the Ras and
the mitogen-activated protein kinase pathway, the phos-
phoinositide 3-kinase pathway, or to the TGF-β-SMAD
pathway, which all lead to Snail expression [30, 31, 35].
Recently, the DNA binding factor LIV1 has been found to
promote activation of Snail through a STAT3-dependent
pathway [42] (Fig. 4).
The matrix protein periostin was shown to be not only a
marker of EMT, but to be itself an inductor of this
phenomenon [26, 27]. Indeed Yan et al. demonstrated that
ectopic expression of periostin in tumorigenic but non-
metastatic 293T cells can induce EMT and promote
invasion and metastasis in vivo [26]. Upregulation of
periostin was accompanied by upregulation of vimentin,
fibronectin, and active MMP-9, while E-cadherin and N-
cadherin expression was unaltered. Periostin signaling
pathway in 293T cells seems to require interaction with
αvβ5 integrin and recruitment of EGFR, as demonstrated
by the fact that periostin-induced increase in cell adhesion,
migration and invasion can be blocked by incubation with
anti-integrin αvβ5 antibody or with tyrphostin 25, an
EGFR kinase inhibitor.
Kim et al. found that periostin was able to induce EMT
and an increased invasiveness in prostate cancer cell lines
by downregulation of E-cadherin via Snail and increased
phosphorylation of Akt [27]. Opposite effects were ob-
served using bladder cancer cell lines, indicating that
periostin regulates E-cadherin in a cell-type-dependent
way. Furthermore, the C-terminal region of periostin was
not sufficient for induction of EMT in prostate cancer cells,
indicating that the induction of EMT is mediated by the N-
terminal region of periostin.
However, examination of the expression pattern of EMT
markers (such as periostin, vimentin, fibronectin, N-
Fig. 4 Drivers and mediators of
EMT. Early stage tumor cells
(green) maintain epithelial
properties similar to the neigh-
boring normal epithelium
(brown). The overexpression of
master regulators of EMT, such
as Twist, Snail, and SIP1 in
cancer cells (shown with purple
nuclei) leads to dramatic
changes in the gene expression
profile and cellular behavior.
Twist, Snail, and SIP1 suppress
the expression of E-cadherin and
trigger expression of an entire
EMT transcriptional program
through as yet unknown mech-
anisms. Reprinted from [31]
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cadherin, E-cadherin, and β-catenin) or members of the
Akt/PKB signaling pathway allows determination of their
occurrence and clinical significance in vivo. Therefore, an
increasing number of immunohistochemical studies aim to
characterize EMT expression profiles and their prognostic
significance.
Periostin expression in different tumor types
Upregulation of periostin has been observed in many cancer
types, such as neuroblastoma [43], head and neck [44],
nasopharyngeal [45], thyroid [46], oral [47], breast [48],
and ovarian cancer [19]. Elevated periostin levels were also
detected in the serum from thymoma [49] and breast [50]
cancer patients as well as in serum and pleural effusions of
lung cancer patients [51, 52]. In the following, recent data
on periostin expression will be described for different tumor
types.
Non-small cell lung cancer
Periostin expression in normal healthy lung tissue has been
observed [9] and its upregulation in cancerous lung tissue
has been reported [16, 53] and associated with EMT [16].
Recently, periostin was identified in malignant pleural
effusions from lung adenocarcinoma by mass spectrometric
N-glycoprotein profiling [52] and its serum levels were
shown to be higher compared with the normal control in
NSCLC. The normal control consisted of pleural effusions
from patients with cardiac disease but no neoplasia.
Soltermann et al. compared the expression of EMT proteins
such as periostin and vimentin, the MET protein versican,
and classical desmoplasia markers such as collagen and
elastin, in NSCLC by immunohistochemical analysis of
tissue microarrays (TMAs). From these studies, it was
derived that stromal periostin is a prognostic factor for
decreased progression-free survival in NSCLC, and together
with epithelial periostin, it was also significantly associated
with several clinicopathological parameters such as squamous
cell carcinoma histotype, higher stage, higher pT, higher pM,
larger tumor size, and vessel infiltration, as well as with male
gender [16]. Moreover, stromal periostin expression was
significantly associated with epithelial cytoplasmic expres-
sion of vimentin and with collagen, but not with elastin,
suggesting that during tumor progression the stromal fibrillo-
genesis in NSCLC may switch from elastin to periostin [16].
However, periostin stromal expression in NSCLC is mostly
due to the intra-tumoral component, rather than to the peri-
tumoral component of the stroma (own unpublished data).
Interestingly, periostin was also correlated with the MET
marker versican [16]; the expression of versican has been
shown to be associated with tumor recurrence and more
advanced disease in NSCLC [54].
Malignant pleural mesothelioma
MPM consists of different histotypes, including epithelioid,
sarcomatoid, and biphasic. The biphasic MPM is a mixed
histotype which is associated with both epithelial and
mesenchymal phenotypes. The sarcomatoid and epithelioid
histotypes resemble the EMT–MET transdifferentiation,
being associated with the epithelial and mesenchymal
differentiation state of the cell, respectively.
Schramm et al. conducted an immunohistochemical
study on more than 350 MPM patients. Members of a
putative MPM–EMT signaling cascade were analyzed: the
EMT marker periostin, the EGFR, integrin β1, the inhibitor
of Akt signaling pathway phosphatase and tensin homolog
(PTEN), the integrin-linked kinase (ILK), and the two cell
cycle regulators, p21 and p27. The results showed that
expression of periostin in tumor cells can be considered as
an independent prognostic factor for overall survival [20].
Indeed high periostin levels in tumor cells correlated with
poor survival, whereas high cytoplasmic PTEN, ILK, or
nuclear p21 and p27 correlated with better survival.
Interestingly, both stromal and tumor cell periostin
expression was associated with the sarcomatoid histotype,
indicating that periostin is associated with the mesenchymal
differentiation state of the cell [20]. Contrary to periostin,
high EGFR and integrin β1 expression nuclear p27 were
associated with the epithelioid histotype of MPM.
Prostate cancer
A limited number of studies have investigated periostin
expression in prostate cancer [9, 28, 55]. Periostin
expression in normal prostate tissue has been detected by
western blot analysis [9]. Tsunoda et al. detected periostin
among several genes by a screening for three-dimensional
culture (3DC)-associated genes. Non-malignant prostatic
epithelial cells, cultured in two-dimensional culture (2DC)
and 3DC, were compared with 40 PC samples and their
matched non-neoplastic prostate epithelium. Candidate
genes were further validated by quantitative real time
(RT)-PCR. Since periostin mRNA showed the highest
levels among all the genes upregulated in 3DC, its protein
expression was further evaluated by immunohistochemistry
(IHC). Cancer cells of early stage but not advanced stage
prostate cancer had an increased periostin expression
compared with normal glands [55]. Tischler et al. [28]
analyzed periostin expression by IHC in more than 400
prostate tumors. Contrary to Tsunoda et al., both stromal
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and epithelial periostin expression was found to be
increased in advanced and metastatic tumors [28]. They
also reported increased periostin expression in the tumor
stroma compared with the stroma around normal prostate
glands. Furthermore, they showed that stromal periostin is
upregulated in high-grade prostate cancers and affirmed
stromal periostin as a progression factor for prostate-
specific antigen relapse-free survival.
Renal cell carcinoma
Periostin was identified as an accessible biomarker from the
blood stream after ex vivo perfusion and biotinylation of
surgically resected human kidney carcinoma [56]. Its tumor
specificity was further confirmed by IHC. Periostin showed
a prominent vascular and stromal staining pattern [56].
Interestingly, the MET protein versican and the EMT
protein periostin were found to have similar stromal
expression patterns in RCC [56] as well as in NSCLC [16].
A bioinformatic network modeling approach, comparing
immunohistochemical stainings from TMAs of RCC
patients, analyzed periostin along with several other
proteins to elucidate molecular pathways influenced by
the von Hippel-Lindau (VHL) gene and the PTEN gene,
which are often deregulated in clear cell RCC [21]. Both
epithelial and a stromal periostin staining was observed. In
particular, epithelial periostin was significantly increased in
high-grade and high-stage tumors and was significantly
associated with poor overall survival [21]. In an estimated
graphical log-linear model, periostin was also found to be
positively associated with nuclear PTEN, phosphorylated
ribosomal protein p-S6, and nuclear p21, whereas cytoplas-
mic PTEN and inactive non-phosphorylated ribosomal
protein S6 correlated with a prolonged survival [21].
Recently, we identified several periostin isoforms in renal
tissue by direct sequencing, one of which was found to be
tumor associated [57].
Hepatocellular and bile duct carcinomas
Periostin has been found to enhance tumor progression in
several gastrointestinal cancers such as colon, gastric, and
pancreatic cancer [17, 58, 59]. Few studies have investi-
gated periostin expression in human liver [18, 29, 60].
Tilman et al. analyzed periostin mRNA levels by quantita-
tive RT-PCR in six HCC and five normal liver samples:
periostin mRNA levels were increased by an average 65-
fold in tumor [60]. Additionally, among various tumor
types, strong periostin upregulation was mostly observed in
liver and pancreatic tumors [60]. Baril et al. analyzed
periostin expression by IHC in multiple tumor types
including 11 HCC: liver tumors showed the highest
periostin levels, together with breast, pancreatic, colon
and larynx tumors. Recently, Riener et al. [29] performed
the first immunohistochemical analysis on a large number
of liver cancer patients (91 HCC and 116 BDC), which
represented also the first report on periostin expression in
BDC. Their study showed that expression of epithelial
periostin was increased in higher-grade HCC and was
shown to be an independent prognostic marker for poor
overall survival in BDC. Periostin expression was also
detected in the stroma of both HCC and BDC but did not
correlate with clinicopathological parameters. Periostin
expression was also analyzed in normal bile ducts,
gallbladder epithelium, and hepatocytes, which showed a
weak periostin cytoplasmic expression.
These immunohistochemical studies show that, depend-
ing on the cancer type, either epithelial or stromal periostin
expression is associated with different tumor behavior
(Table 1). One might hypothesize the existence of an
autocrine/paracrine periostin loop between stromal and
epithelial tumor cells and that the protein is secreted at a
site where it can exert its strongest effect, namely at the
interface between tumor and stroma. Furthermore, different
splice variants of periostin might result in different
biological effects, if they are secreted either by tumor
stromal cells or by tumor epithelial cells.
Periostin isoforms and alternative splicing
Up to six different splice isoforms of periostin have been
reported, four of which have been fully sequenced and
annotated [3, 56] (Table 2). The isoforms of periostin are
between 83 and 93 kDa in mass and differ in their C-
terminal sequences, characterized by individual presence or
absence of cassette exons 17–21 (UniProtKB/Swiss-Prot,
March 2011); its N-terminus is conserved. Periostin iso-
forms were initially detected in pre-osteoblast cells, and it
has been shown that the levels of osteoblast-specific
differentiation markers were markedly reduced when the
activity of these proteins was blocked in the mouse
Table 2 Schematic representation of the periostin cassette exons in
the four known isoforms (isoforms 1–4)
Isoform Exon
1 1–16 17 18 19 20 21 22–23
2 1–16 19 20 21 22–23
3 1–16 18 19 20 22–23
4 1–16 19 20 22–23
Periostin splice isoforms are characterized by an individual presence
or absence of cassette exons 17–21
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osteoblast cell line MC3T3-E1. These results suggest that
these proteins play a role in the differentiation of
osteoblasts [3].
The periostin C-terminal domain probably modulates the
protein function by binding to ECM molecules such as
fibronectin and collagen [61]. Indeed, Norris et al.
demonstrated that the C-terminal domain of periostin binds
collagen I, concluding that it is involved in fibrillogenesis
and influences the biomechanical properties of fibrous
connective tissues [4]. On the basis of comparative studies
of periostin sequences among vertebrates, Hoersch and
Andrade-Navarro suggested that the C-terminal domain of
periostin is able to bind the matrix proteins collagen and
fibronectin, and that each isoform may exert its influence
on the ECM fibrillogenesis differently [61]. Therefore,
alternative splicing of periostin isoforms seems to reflect
the differential modulation of the periostin function in the
ECM. This hypothesis is supported by the finding that
downregulation and/or loss by alternative splicing of the
periostin non-spliced form, together with expression of
variant I (isoform 4 in UniProtKB/Swiss-Prot database),
promotes increased invasiveness in in vitro and in vivo
experiments using the human bladder cancer cell line
SBT991, the mouse malignant melanoma cell line
B16F10, and nude mice [22, 62]. Given that periostin
isoforms have a differential invasive potential, it remains to
be clarified how exactly periostin isoforms modulate the
ECM formation and if this periostin-isoform-modulated
ECM formation has an influence on the global invasive and
metastatic potential of the protein.
Alternative splicing contributes to the expansion of
transcriptomic diversity. It is achieved by the interplay of
several RNA-binding proteins that associate with pre-
mRNA transcripts, determining an exon skipping or
inclusion in the mature RNA transcript [63]. Several
ubiquitous families of proteins that regulate splicing have
been identified and they act in cooperation with tissue-
specific regulators of splicing [64]. Warzecha et al.
identified the epithelial splicing regulatory proteins 1 and
2 (ESRP1 and ESRP2) as cell-type-specific regulators of
transcripts that switch splicing during the EMT [65]. Those
two RNA-binding proteins promote alternative splicing
events with function in cell–cell adhesion, polarity, and
migration, influencing the phenotypic morphological
changes that are observed in the EMT. This complex
alternative splicing network reveals an important post-
transcriptional aspect in addition to the changes in gene
expression that underlie the EMT. In particular, it was
shown that downregulation of the ESRPs leads to an
increase in exon skipping events in the penultimate exons
of the C-terminal transcript regions of all analyzed proteins.
These events are thought to be functionally relevant
because the skipped exons were in multiples of three
nucleotides, allowing translation into different protein
isoforms. Even though periostin was not identified among
the transcripts regulated by ESRP1 and ESRP2, periostin
isoforms are generated by alternative splicing in the
penultimate exons of the C-terminal transcript region and
the skipped exons are in multiples of three. Therefore it is
possible that periostin transcripts are regulated during EMT
by specific splice-regulatory proteins and that those tran-
scripts have an influence on the morphologic and functional
changes associated with the EMT.
Periostin as a target for immunotherapy
In RCC, periostin was found to be overexpressed in the
subendothelial stroma of the tumor neovasculature [56]. It
was suggested that periostin represents a potential target for
anticancer therapies directed against the subendothelial
stroma (so called “tumor vascular targeting” [66]). Indeed,
the tumor neovasculature is tumor specific and discrete
from normal adult tissue, except for a local and transient
angiogenesis that occurs during specific processes such as
tissue regeneration and inflammation [67].
Castronovo et al. found periostin to be an accessible
antigen from the blood stream after ex vivo perfusion and
biotinylation of surgically resected human renal carcinomas
[56]. The ex vivo biotinylation of surgically resected renal
carcinomas allowed a selective labeling of tumor vascular
structures. Subsequent proteomic analysis of the biotiny-
lated specimens allowed the identification of several
proteins in the tumor portions, including periostin, which
was the most abundant tumor-associated protein identified
in RCC [56]. Validation of periostin as a tumor-associated
antigen was performed by IHC and PCR. IHC showed
overexpression of periostin in tumor samples, with a
prominent vascular and stromal pattern of staining. PCR
analysis yielded stronger periostin expression in fetal and
tumor specimens [56]. These data suggested that oncofetal
periostin variants might represent even more specific tumor
targets.
In conclusion, upregulation in tissues and body fluids of
many tumor types, accessibility from the blood stream, and
correlation with malignant behavior and with poor progno-
sis speak in favor of the potential usefulness of periostin as
a target for immunotherapy. Further, ECM proteins such as
periostin, fibronectin, or tenascin C belong to a class of
proteins that can be considered suitable tumor antigens for
targeted delivery of therapeutic agents because of their
accessibility, specificity, stability, and abundance [56, 66].
The therapeutic potential of periostin has recently been
evaluated by Castronovo et al. [56] and by Kudo et al. [68],
with the conclusion that stroma-targeting represents a valid
option in anticancer therapy.
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